Preclinical Safety, Efficacy And Pharmacokinetics Of OBI-1, A Recombinant Porcine FVIII

被引：0
|
作者：
Schiviz, A. [1 ]
Piskernik, C. [1 ]
Leidenmuehler, P. [1 ]
Putz, M. [1 ]
Hoellriegl, W. [1 ]
机构：
[1] Baxter Innovat GmbH, Vienna, Austria
来源：
HAEMOPHILIA | 2015年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
PP082
引用
收藏
页码：62 / 63
页数：2
相关论文
共 50 条
  • [1] Preclinical safety of OBI-1, a recombinant porcine sequence FVIII product
    Schiviz, Alexandra
    Hoellriegl, Werner
    Piskernik, Christina
    Leidenmuehler, Peter
    Muchitsch, Eva-Maria
    Dietrich, Barbara
    [J]. HAEMOPHILIA, 2014, 20 : 2 - 2
  • [2] Pharmacokinetics of OBI-1, a recombinant porcine sequence FVIII product, in macaques and hemophilic dogs
    Hoellriegl, Werner
    Schiviz, Alexandra
    Piskernik, Christina
    Leidenmuehler, Peter
    Muchitsch, Eva-Maria
    [J]. HAEMOPHILIA, 2014, 20 : 1 - 2
  • [3] Efficacy of OBI-1, a recombinant porcine sequence FVIII product, in animal models of hemophilia A
    Schiviz, Alexandra
    Piskernik, Christina
    Leidenmuehler, Peter
    Muchitsch, Eva-Maria
    Hoellriegl, Werner
    [J]. HAEMOPHILIA, 2014, 20 : 2 - 2
  • [4] Elucidation of structure and functional characteristics of OBI-1, a recombinant, porcine sequence FVIII
    Lai, C. K.
    Tse, Albert
    Sivakollundu, Sivashankar
    Patel, Mayank
    Vangala, Swathi
    Zhang, Li
    Wojciechowski, Peter
    [J]. HAEMOPHILIA, 2014, 20 : 180 - 180
  • [5] NON-CLINICAL DEVELOPMENT OF OBI-1, A RECOMBINANT PORCINE SEQUENCE FVIII PRODUCT
    Hoellriegl, Werner
    Schiviz, Alexandra
    Piskernik, Christina
    Leidenmuehler, Peter
    Dietrich, Barbara
    Muchitsch, Eva-Maria
    [J]. AMERICAN JOURNAL OF HEMATOLOGY, 2014, 89 (06) : E37 - E38
  • [6] Non-clinical immunogenicity assessment of a new recombinant porcine sequence FVIII (OBI-1)
    Allacher, Peter
    Horling, Frank
    Piskernik, Christina
    Leidenmuehler, Peter
    Reipert, Birgit
    [J]. HAEMOPHILIA, 2014, 20 : 2 - 2
  • [7] Efficacy and safety of OBI-1, an antihaemophilic factor VIII (recombinant), porcine sequence, in subjects with acquired haemophilia A
    Kruse-Jarres, R.
    St-Louis, J.
    Greist, A.
    Shapiro, A.
    Smith, H.
    Chowdary, P.
    Drebes, A.
    Gomperts, E.
    Bourgeois, C.
    Mo, M.
    Novack, A.
    Farin, H.
    Ewenstein, B.
    [J]. HAEMOPHILIA, 2015, 21 (02) : 162 - 170
  • [8] Pharmacokinetics and safety of OBI-1, a recombinant B domain-deleted porcine factor VIII, in subjects with haemophilia A
    Kempton, C. L.
    Abshire, T. C.
    Deveras, R. A.
    Hoots, W. K.
    Gill, J. C.
    Kessler, C. M.
    Key, N. S.
    Konkle, B. A.
    Kuriakose, P.
    Macfarlane, D. E.
    Bergman, G.
    [J]. HAEMOPHILIA, 2012, 18 (05) : 798 - 804
  • [9] The Benefit of FVIII Measurement: Tailored Treatment with Obi-1, a Recombinant Porcine Sequence Factor VIII, in Subjects with Acquired Hemophilia a
    Oladapo, Abiola
    Epstein, Joshua
    Novack, Aaron
    Farin, Heinrich D.
    [J]. BLOOD, 2014, 124 (21)
  • [10] Effect of OBI-1, a recombinant FVIII product with porcine FVIII sequence, on thrombin generation and clot structure in plasma from hemophilia A patients with inhibitors
    Negrier, Claude
    Oldenburg, Johannes
    Poetzsch, Bernd
    Bordet, Jean-Claude
    Al Dieri, Raed
    Dargaud, Yesim
    Hemker, Coen
    Lee, Martin
    Turecek, Peter L.
    [J]. HAEMOPHILIA, 2014, 20 : 3 - 3
12345